Derma Sciences

Derma Sciences is a Medical Devices company specializing in the field of Advanced Wound Care. Currently their major products are Medihoney, Algicell AG, Xtrasorb wound dressing, Bioguard and Mobility1. Their newest product DSC127 - an Angiotensin Analog - is currently in Phase II Pre-Clinical trials.
Type
Public
HQ
Princeton, US
Employees
260 (est)-13%
Derma Sciences is headquartered in Princeton, US

Key People at Derma Sciences

Edward J. Quilty

Edward J. Quilty

Chairman & CEO
Srini Conjeevaram

Srini Conjeevaram

Director
John E. Yetter

John E. Yetter

CFO & Vice President of Finance

Derma Sciences Locations

Princeton, US
New York, US

Derma Sciences Metrics

Derma Sciences Summary

Market capitalization

$196 M

Closing share price

$7
Derma Sciences's current market capitalization is $196 M.

Derma Sciences Financials

Derma Sciences's revenue is $84.5 M in FY, 2015 which is 0.87% increase from the previous period.
FY, 2014FY, 2015

Revenue

$83.7 M$84.5 M

Gross profit

$30.1 M$32.7 M

Operating income

$-40.1 M$-22 M

Operating expense total

$70.2 M$54.7 M

Net Income

$-39.8 M$-38.1 M

Operating cash flow

$12.9 M$-3.58 M

    Derma Sciences Market Value History

    Derma Sciences Online Presence

    Derma Sciences News

    Derma Sciences Company Life

    You may also be interested in